An interventional study of kalifilcon A Daily Disposable Multifocal and samfilcon A for Presbyopia in Presbyopia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Presbyopia by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Presbyopia · Bausch Health Companies Inc..
Among the 26 studies in Presbyopia by Bausch Health Companies Inc., this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 with no phase, and was the 21st registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →2 of the 26 studies in Presbyopia by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:
Bausch & Lomb Incorporated · Sites in United States
Ages 22+
AcuFocus, Inc.
Ages 45–60 · Healthy volunteers
By country, each count listing its studies:
Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2022.
This study's enrollment of 30 is below the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 99 across the 20 interventional studies, 151 across the 6 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
1 of the studies in Presbyopia by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06060041Bausch & Lomb IncorporatedIC-8 Apthera IOL New Enrollment Post Approval Study | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Presbyopia by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Experienced soft contact lens wearing subjects will be enrolled in this 1-week, confirmatory, randomized, bilateral, 2-way crossover, double masked (subject and investigator), repeated measures, dispensing study. All subjects will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If subjects satisfy all eligibility criteria and none of the exclusion criteria, subjects will be fit and dispensed study lenses according to unique randomization schedules that will be provided to each Investigator If vision is unsatisfactory in the original dispensed lenses, additional lens powers may be trialed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants wore kalifilcon A Daily Disposable Multifocal (Low Add and High Add) lenses bilaterally, daily-disposable/single-use, for approximately 1 week, then crossed over to Ultra for Presbyopia (samfilcon A) Low and High Add lenses bilaterally, daily-disposable, for approximately 1 week.
Device: kalifilcon A Daily Disposable Multifocal · Device: samfilcon A for Presbyopia
Participants wore Ultra for Presbyopia (samfilcon A) Low and High Add lenses bilaterally, daily-disposable/single-use, for approximately 1 week, then crossed over to kalifilcon A Daily Disposable Multifocal (Low Add and High Add) lenses bilaterally, daily-disposable, for approximately 1 week.
Device: kalifilcon A Daily Disposable Multifocal · Device: samfilcon A for Presbyopia
kalifilcon A Daily Disposable Multifocal contact lenses (Low Add \[LD191001\] and High Add \[LD191002\] designs), worn bilaterally on a daily-disposable, single-use basis (≥8 hours/day) for approximately 1 week.
Ultra for Presbyopia (samfilcon A) Low and High Add contact lenses, worn bilaterally on a daily-disposable, single-use basis (≥8 hours/day) for approximately 1 week.
Visual Acuity (Distance)
Mean Binocular logMAR Visual Acuity at Distance (6m)
Time frame: One week (follow-up visit)
Visual Acuity (Near)
Mean Binocular logMAR Visual Acuity at Near (40cm)
Time frame: One week (follow-up)
30 patients were screened for eligibility between February 25, 2022 and March 15, 2022.
| Milestone | Kalifilcon A Daily Disposable Multifocal First, Then Samfilcon A for Presbyopia | Samfilcon A for Presbyopia First, Then Kalifilcon A Daily Disposable Multifocal |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
| Milestone | Kalifilcon A Daily Disposable Multifocal First, Then Samfilcon A for Presbyopia | Samfilcon A for Presbyopia First, Then Kalifilcon A Daily Disposable Multifocal |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Mean Binocular logMAR Visual Acuity at Distance (6m)
| logMAR | Kalifilcon A Daily Disposable Multifocal (Test) | Ultra (Samfilcon A) for Presbyopia (Comparator) |
|---|---|---|
| Visual Acuity (Distance) | -0.091 ± 0.0788 | -0.074 ± 0.0691 |
Mean Binocular logMAR Visual Acuity at Near (40cm)
| logMAR | Kalifilcon A Daily Disposable Multifocal (Test) | Ultra (Samfilcon A) for Presbyopia (Comparator) |
|---|---|---|
| Visual Acuity (Near) | 0.179 ± 0.1679 | 0.182 ± 0.1771 |
Collected over Approximately 2 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kalifilcon A Multifocal (Test) | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Ultra (Samfilcon A) for Presbyopia (Comparator) | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
One participant was discontinued / lost to follow-up and was not included in the data. 30 were enrolled and 29 completed the study and included in the data.
| Age, Continuous(Years) | Total - All Participants, Combined Across Treatment Sequences |
|---|---|
| Mean | 53.9 ± 5.5 |
| Sex: Female, Male(Participants) | Total - All Participants, Combined Across Treatment Sequences |
|---|---|
| Female | 13 |
| Male | 16 |
| Race and Ethnicity Not Collected(Participants) | Total - All Participants, Combined Across Treatment Sequences |
|---|
| Region of Enrollment(participants) | Total - All Participants, Combined Across Treatment Sequences |
|---|---|
| United States | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Mar 2022, 1 month.
Results were first posted in Aug 2026, 4 years 4 months after primary completion.
Of 89 industry-sponsored interventional studies with no phase under Presbyopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's 1 month is below that.
Counting every sponsor, half of 131 studies reached it within 11 months; a quarter within 3 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.